Following the recent provisional decision by the National Institute for Health and Care Excellence (NICE) not to approve dinutuximab beta (Qarziba™) for use on the NHS in England and Wales, we have updated our briefing document.

This was produced by Nick Bird (Parent, Research and Advocacy Trustee and member of the National Cancer Research Institute Children’s Cancer & Leukaemia Clinical Studies Group).

It sets out: a summary of the recent decision; next steps in the process; background context on this antibody therapy and the decision-making process for its use; and the impact for families of children with high-risk neuroblastoma.

This post is an update to the previous one published in March 2018.